குறியிடப்பட்டது
  • அகாடமிக் ஜர்னல்ஸ் டேட்டாபேஸ்
  • ஜெ கேட் திறக்கவும்
  • ஜெனமிக்ஸ் ஜர்னல்சீக்
  • கல்வி விசைகள்
  • JournalTOCகள்
  • சீனாவின் தேசிய அறிவு உள்கட்டமைப்பு (CNKI)
  • Ulrich's Periodicals Directory
  • எலக்ட்ரானிக் ஜர்னல்ஸ் லைப்ரரி
  • RefSeek
  • ஹம்டார்ட் பல்கலைக்கழகம்
  • EBSCO AZ
  • OCLC- WorldCat
  • SWB ஆன்லைன் பட்டியல்
  • உயிரியல் மெய்நிகர் நூலகம் (vifabio)
  • பப்ளான்கள்
  • மருத்துவக் கல்வி மற்றும் ஆராய்ச்சிக்கான ஜெனீவா அறக்கட்டளை
  • யூரோ பப்
  • கூகுள் ஸ்காலர்
இந்தப் பக்கத்தைப் பகிரவும்
ஜர்னல் ஃப்ளையர்
Flyer image

சுருக்கம்

Desensitization to Allopurinol in Localized and Systemic Hypersensitivity Reactions

Gomes R, Ribeiro F, Faria E, Loureiro C and Segorbe-Luís A

Introduction: Allopurinol is, by far, the most frequently prescribed drug for the treatment of hyperuricemia, and the lack of alternatives makes, in case of a reaction, a desensitization procedure to be considered. With this survey, we aimed to do a characterization of patients with hypersensitivity (HS) reactions to allopurinol, who endured desensitization procedures.

Material and methods: Retrospectively, we analyzed the medical files of a group of patients that fit into our objective and were observed in our Department of Immunoallergology of Coimbra University Hospital, between 2007/2012. Demographic data, pathology underlying all prescriptions and concomitant diseases/regular medication, the desensitization protocol and all adverse reactions were taken into consideration.

Results: Six out of seven patients were male, aged from 37 to 79 (mean age of 64 ± 14 years) when undergoing the procedure. As far as the kind of reaction was concerned, three of the patients presented a fixed erythema, two urticaria with/without angiodema, one anaphylaxis and another one maculopapular rash at the time of desensitization. Five of them had gouty joint pathology, one hyperuricemia with chronic renal failure and another had both. Six among all of them presented associated cardiovascular pathology and were polymedicated. \\\\\\\\\\\\\\\\

The desensitization protocol used was adapted from Umpiérrez, with an initial dose of 10 μg up to 300 mg/day, adjusted in case of adverse reaction. There were no complications in three patients and the remaining had mild/ moderate skin reactions. In four patients with HS reaction during desensitization, only three needed to decrease the dose. The maintenance dose was achieved by extending the length of desensitization, between sixteen to twentytwo days.

Conclusion: In this series, the majority of patients had HS reactions during desensitization protocol and dose adjustment was necessary. However, we managed to achieve a maintenance dose in all of them.

மறுப்பு: இந்த சுருக்கமானது செயற்கை நுண்ணறிவு கருவ